|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Agent 9/29/17 Acasti Pharma Inc. F-1 9:4.6M Donnelley … Solutions/FA |
Document/Exhibit Description Pages Size 1: F-1 Registration Statement by a Foreign Private Issuer HTML 1.46M 2: EX-10.1 Material Contract HTML 209K 3: EX-10.2 Material Contract HTML 48K 4: EX-10.5 Material Contract HTML 41K 5: EX-10.6 Material Contract HTML 42K 6: EX-10.7 Material Contract HTML 37K 7: EX-10.8 Material Contract HTML 43K 8: EX-23.1 Consent of Experts or Counsel HTML 8K 9: EX-99.1 Miscellaneous Exhibit HTML 8K
| EX-10.5 |
Exhibit 10.5
EXECUTIVE EMPLOYMENT AGREEMENT
THIS EXECUTIVE EMPLOYMENT AGREEMENT (the “Agreement”) is made this 25th day of November, 2016 (the “Signature Date”) between ACASTI PHARMA INC. (the “Company”) and Linda P. O’ Keefe (the “Executive”) (collectively referred to as the “Parties”)
RECITALS:
| A. | The Executive has valuable skills and experience which will be of assistance to the Company in managing its business in the challenging and rapidly changing business environment in which it operates. |
| B. | The Company has offered the Executive employment on the terms set out in this Agreement, and the Executive has accepted the Company’s offer, effective on the Effective Date (as defined below). |
THEREFORE, the Parties agree as follows:
SECTION 1: DUTIES AND RESPONSIBILITIES
| 1.1 | Position |
Starting on November 27, 2016 (the “Effective Date”), the Executive will be employed at full-time by the Company as its Chief Financial Officer (“CFO”). The Executive will carry out those duties, responsibilities and reporting requirements which are ordinarily expected of a CFO, and such other reasonable duties as may from time to time be assigned by the CEO or the Board of Directors. Starting on the Effective Date, the Executive could serve as a director and officer of any affiliate(s) without further compensation. The Executive will be fully covered under the Company’s D&O insurance policy. The Company will also indemnify the Executive in accordance with the Company’s General By-Laws.
Full Time and Attention and Fiduciary
The Executive shall devote full working time and attention in the performance of the Executive’s duties with the Company and its affiliates. While an employee of the Company, the Executive will not, without obtaining the prior written consent of the Company, assume any other employment or engage in any other business, occupation or directorship, other than as a director of boards of directors for (i) charitable organizations or (ii) industry organizations related to the business of the Company. The Executive is a fiduciary of the Company and shall act at all times in the Company’s best interests.
| 1.2 | Location |
The Executive’s office shall be virtual. It is the expectation that the Executive will operate out of the Company’s headquarters in the Montreal area between six (6) and eight (8) days per calendar month.
| 1.3 | Compliance with Rules and Policies |
The Executive will comply with all Company rules and policies provided or made available to her, including the Code of Conduct and Insider Trading policy. The Company may, from time to time, amend, alter, change, delete or establish new rules and policies (collectively, the “Revised Policies”) to meet the business needs of the Company. The Executive agrees that, immediately upon receiving notice of and access to such Revised Policies, the Executive’s employment will be governed by such Revised Policies.
SECTION 2: REMUNERATION
| 2.1 | Base Salary |
The Executive will be paid an annual salary in the amount of US$250,000 (the “Base Salary”), payable in accordance with the Company’s payroll practices for non-resident employees, as may be amended from time to time. Future increases in Base Salary (if any) will be at the sole discretion of the Board.
| 2.2 | Annual At Risk Incentive Compensation |
| (a) | The Executive will be eligible to earn an annual bonus (the “Bonus”) based on the achievement of metrics and goals established and evaluated by the Board, in its sole discretion. The target Bonus will be 20% of Base Salary and the maximum Bonus will be 30% of Base Salary and will be based on performance targets set by the Board. There is no representation that a Bonus in one year will be comparable to another year and under no circumstances is the Bonus to be considered part of the Executive’s Base Salary or other regular employment income. The Bonus for the Executive in the first year of employment will be pro-rated to the number of months of active employment completed by the Executive during that fiscal year. |
| (b) | The Bonus, if any, will be paid when the Company normally pays such Bonuses, and no later than 60 days following each applicable fiscal year end. If prior to the year end, the Executive’s active employment with the Company ceases at the Executive’s discretion, no Bonus will be paid. If, however, the Executive has received notice of termination, other than for cause, the Executive will still be eligible to earn a Bonus, pro-rated to the number of months of active employment completed by the Executive during that fiscal year, based on the achievement of metrics and goals established and evaluated by the Board, in its sole discretion, for that fiscal year. |
| 2.3 | Stock Options |
| (a) | The Executive shall be eligible to participate in the Company’s Stock Option Plan, as approved by the Board and as amended from time to time (the “Stock Option Plan”). The vesting of stock options (“Options”), and the subsequent exercise of such Options shall be governed in all respects by the Stock Option Plan and the grant documents. |
- 2 -
| (b) | Subject to the approval of the Board of Directors, the Executive shall be eligible to receive an initial Option grant to purchase common shares of the Company at a strike price per option equal to the closing price of the Company’s common shares on the TSXV on the eve of the grant date (the “Initial Grant”). The grant document(s) shall provide that vesting of the award will begin on the grant date and will occur on an equal quarterly basis over two (2) years and seven (7) months and expire after seven (7) years. |
| (c) | The grant documents will contain customary terms and conditions for awards of this nature, including specific provisions pursuant to which (i) At the request of the Executive, all or part of the options under the Initial Grant will be identified as incentive stock options (ISO) intended to qualify under Section 422 of the United States Internal Revenue Code of 1986 and the applicable authority thereunder (the “Code”) (ii) vesting of all unvested options shall become fully vested as of the effective date of a change of control of the Company (as defined under the grant documents and the amended Stock Option Plan), (iii) upon a termination by the Company without cause, the vested portion of the Options, as of the termination date, will expire on the lesser of a) the period of time remaining until the expiry date, as set forth in the grant documents; and b) 12 months following the termination date, and (iv) the Company will expressly decline any repurchase right of the Options granted to the Executive. |
| (d) | The Executive will be eligible to receive additional annual grants. The quantum of such grants shall be set by the Board of Directors, in its discretion, having regard to Company practice and performance and the provisions of the Stock Option Plan, as amended from time to time. |
| 2.4 | Benefits |
The Company agrees to reimburse the Executive up to 50% of her U.S. medical, dental and vision insurance premium (estimated at approximately US$650 per month as of the Effective Date) upon submission of proper documentation and receipts evidencing the same. The Company also agrees to cover 100% of any additional equivalent insurance coverage for her stay in Canada, if required.
| 2.5 | Vacation |
The Executive’s annual vacation entitlement will be four (4) weeks per year. The Executive is required to arrange vacation time to suit the needs of the Company. Vacation entitlements, including treatment of unused vacation time, shall be in accordance with the Company’s vacation policy.
| 2.6 | Reimbursement of Expenses – |
| (a) | The Company agrees to reimburse the Executive for any reasonable out of pocket expenses incurred in the course of performing her employment duties. Reimbursement will be conditional upon the Executive providing an itemized account and receipts. The Company may also provide the Executive with a credit card for such purposes and to facilitate the same. |
- 3 -
| (b) | The Company shall also reimburse the Executive for the following expenses: |
| (i) | Economy air flights between Executive domiciliary location and Montreal office of the Company; |
| (ii) | Hotel, car rental and other associated expenses for office time at the Montreal office of the Company; |
| (iii) | Home office expenses including the following: office supplies, postage, internet services, local and long-distance (including international service) call plans (for land line and cell phone), laptop computer, business cell phone and IT services. |
| (iv) | Canadian tax preparations and filings |
| (v) | Business laptop, monitor and a docking station in the Company’s headquarters in Montreal; |
| (vi) | 50% of the annual cost of the Executive maintaining an active U.S.- originating CPA license, as long as that cost does not exceed U.S.$1,500 per year. Such reimbursable costs include the license issuance costs, membership in the AICPA for its CPA and CGMA designations, and the cost of the education required to maintain this active license, and |
| (vii) | Any other reasonable business expenses as covered in the Company’s board approved budget (for example, this could include taking a consultant to lunch, or attendance at a conference). |
SECTION 3: TERMINATION OF EMPLOYMENT
| 3.1 | Termination by the Company for Cause |
The Company may terminate the Executive’s employment at any time for good and sufficient cause. “Cause” shall notably mean, but is not limited to: (i) an act of material dishonesty made by Executive in connection with Executive’s carrying out her job responsibilities to Company that is intended to benefit Executive directly or indirectly, (ii) Executive’s conviction of, or plea of nolo contender to, a felony which the Board reasonably believes had or will have a material detrimental effect on the Company’s reputation or business, and (iii) a willful act by the Executive which constitutes gross misconduct and which is injurious to the Company or its affiliates. The expression “good and sufficient cause” should be interpreted the same way as Quebec Tribunals interpret and apply it.
If the Executive’s employment is terminated for cause, except as may be required by applicable employment standards legislation, no notice and/or severance will be provided.
- 4 -
| 3.2 | Termination by the Company without Cause or Upon Change of Control |
| (a) | Severance Payments. The Company may terminate the Executive’s employment at any time without cause by providing the Executive with a 30-day notice of termination, and afterwards, payment of Base Salary, equal to three months (the “Severance Period”).The Company is obligated to make payment of Base Salary, equal to twelve (12) months, should the Executive be terminated upon a “Change of Control” event, as such term is defined under the Corporation Stock Option Plan. |
| (b) | The foregoing arrangements set out in (a) fully satisfy the Company’s and all affiliates’ obligations to the Executive in respect of the termination of her employment and she will not be entitled to further notice of termination or severance pay under common law, civil law or contract. The Executive irrevocably acknowledges and agrees that the foregoing arrangements constitute full compensation in lieu of any reasonable notice to which the Executive may claim to be entitled, now or in the future. |
| 3.3 | Termination by Executive With Notice |
If the Executive decides to resign from employment, the Executive will provide the Company with at least 60 days’ advance written notice. The Company may upon written notice, at any time during such notice period, relieve the Executive from all or any of her duties for all or part of the remainder of the notice period. This may include a requirement that the Executive must stay away from all or any of the Company’s premises and/or will not be provided with any work. Whether or not the Executive is relieved of any duties, during the notice period, the Executive will be paid Base Salary and other benefits in accordance with this Agreement; the Executive’s employment will not be terminated by any removal of duties and her employment will continue during the notice period and the Executive will continue to be bound by her obligations under this Agreement.
| 3.4 | Termination by Executive With Good Reason |
| (a) | For the purpose of this article 3.4,“Good Reason” shall mean without Executive’s express written consent substantial changes to the essential conditions of employment of the Executive, such as (i) a significant reduction or adverse change in Executive’s duties, position, reporting relationship or responsibilities, or the removal of Executive from such duties, position or responsibilities; (ii) a significant reduction by the Company in the Base Salary of Executive as in effect immediately prior to such reduction, other than a reduction applicable to all members of Company management; (iii) an Initial Grant significantly less than 200,000 Options; (iv) the relocation of Executive to a facility or a location more than forty (40) miles from Executive’s then present employment location. In addition, Executive must provide written notice to the Company of the existence of the one or more of the above conditions within ninety (90) days of its initial existence and the Company must be provided with thirty (30) days to cure the condition. If the condition is not cured within such thirty (30) day period, the Executive must terminate employment within thirty (30) days of the end of such cure period in order to qualify as a termination for Good Reason. |
| (b) | Severance Payments. If the Executive terminates her employment with the Company in accordance with the provisions under 3.4(a), except under 3.4 (a) (iii) the Company is obligated to make payment of Base Salary, equal to the Severance Period, plus any Bonus payable under Section 2.2(b), if any. If the Executive terminates her employment with the Company in accordance with the provisions under 3.4(a) (iii), the Company is obligated to make payment of Base Salary, equal to one-third (1/3) of the Severance Period |
- 5 -
| (c) | The foregoing arrangements set out in (b)3.4(b) fully satisfy the Company’s and all affiliates’ obligations to the Executive in respect of the termination of her employment and she will not be entitled to further notice of termination or severance pay under common law, civil law or contract. The Executive irrevocably acknowledges and agrees that the foregoing arrangements constitute full compensation in lieu of any reasonable notice to which the Executive may claim to be entitled, now or in the future. |
| 3.5 | Actions Required Upon Termination |
Upon termination of the Executive’s employment for any reason, the Executive shall (i) upon the request of the Company, re-confirm and acknowledge the Executive’s agreement to be bound by the covenants and restrictions in SECTION 4, (ii) promptly return all Company property and records, in whatever form, to the Company and (iii) upon the request of the Company, immediately resign from any and all director or officer positions he may hold with the Company or its affiliates.
SECTION 4: EXECUTIVE COVENANTS
| 4.1 | Non-Disparagement |
The Executive shall not assist with, engage in or authorize the making or publishing of written or oral statements or remarks which are disparaging, deleterious or damaging to the integrity, reputation or goodwill of the Company, any affiliates, and/or their management.
The Company shall not assist with, engage in or authorize the making or publishing of written or oral statements or remarks which are disparaging, deleterious or damaging to the integrity, reputation or goodwill of the Executive.
| 4.2 | Confidential Information and Intellectual Property |
The Executive shall sign and be bound by the standard Company’s Confidentiality and Intellectual Property Agreement.
| 4.3 | Non-Competition |
The Executive will not, either while employed with the Company or for a period of twelve (12) months subsequent to the Executive’s termination of employment for any reason, without the Company’s express written consent, either as an individual, or in conjunction with any other person, firm, corporation, or other entity, whether acting as a principal, agent, professional, manager, executive, consultant or similar capacity, engage in or in any way be concerned with any competitor of the Company within Canada or the United States. For the purposes of this Section and Section 4.5, a competitor of the Company is any business engaged in the development, manufacturing or commercialization of marine-derived omega-3 phospholipids, whether extracted from krill or from other marine sources, for any application or in any industry, including the nutraceutical or pharmaceutical industries. Should the Company business cease given it has not been able to fund its continued operations, then this section 4.3 will no longer be applicable.
- 6 -
| 4.4 | Non-Solicitation and Non-Interference |
The Executive will not, either while employed with the Company or for a period of twelve (12) months subsequent to the Executive’s termination of employment for any reason, without the Company’s express written consent, either as an individual, or in conjunction with any other person, firm, corporation, or other entity, whether acting as a principal, agent, manager, executive, consultant or similar capacity, within Canada and the United States or any other country in which the Company carries on a business for which the Executive had responsibilities in last five (5) years of employment:
| (a) | solicit, attempt to solicit, or communicate in any way with any employees or full-time consultants of the Company for the purpose of having such employees employed or in any way engaged by another person, firm, corporation, or other entity. |
| 4.5 | Acknowledgement |
Due to the sensitive nature of the Executive’s position and the special access that the Executive will have to the Company’s confidential information and intellectual property, the Executive will be in a position to irreparably harm the Company should the Executive (either during the Executive’s term of employment with the Company, or subsequent to the termination of such employment) enter into competition with the Company (directly or indirectly) or otherwise make use of the specialized knowledge, contacts and connections obtained during the Executive’s employment to the detriment of the Company. The Executive acknowledges that the unauthorized use or disclosure of such information could irreparably damage the Company’s interests if made available to a competitor, or if used against the Company for competitive purposes. The Executive agrees that the covenants and restrictions contained in this Section 4 are reasonable and valid in terms of time, scope of activities and geographical limitations and understands and agrees that they are vital consideration for the purposes of the Company entering into this Agreement. Competition in this section will be considered as defined in section 4.3.
SECTION 5: GENERAL
| 5.1 | Eligibility to Perform Services |
| 5.2 | The Executive hereby represents and warrants that (i) the Executive is not bound by any agreement, including any restrictive covenants, that may restrict the Executive from accepting employment with the Company and performing the duties assigned to her pursuant to this agreement. Severability |
If, in any jurisdiction, any provision of this Agreement or its application to either Party or circumstance is restricted, prohibited or unenforceable, the provision shall, as to that jurisdiction, be ineffective only to the extent of the restriction, prohibition or unenforceability without invalidating the remaining provisions of this Agreement and without affecting the validity or enforceability of such provision in any other jurisdiction, or without affecting its application to other parties or circumstances.
- 7 -
| 5.3 | Entire Agreement |
This Agreement, including the attached schedules and the agreements and other documents referenced in this Agreement, constitute the entire agreement between the Parties in respect of the employment of the Executive, and supersede and replace any and all prior agreements, understandings, representations, negotiations and discussions, whether express or implied, oral or written, pre-contractual or otherwise.
| 5.4 | Legal Advice |
The Executive acknowledges that the Executive has read and understands the terms and conditions contained in this Agreement, and that the Company has provided a reasonable opportunity for the Executive to seek independent legal advice prior to executing this Agreement.
| 5.5 | Governing Law |
This Agreement is a contract made under and shall be governed by and construed in accordance with, the laws of the Province of Quebec and the federal laws of Canada applicable in the Province of Quebec.
| 5.6 | Currency and Withholding |
Unless otherwise specified, all references to money amounts are to the lawful currency of United States. All payments made by the Company to the Executive or for the benefit of the Executive shall be less applicable non-resident withholdings and deductions.
| 5.7 | Interpretation and Language |
The language used in this Agreement shall be deemed to be the language chosen by the Parties to express their mutual intent, and the Agreement shall be interpreted without regard to any presumption or other rule requiring interpretation of the Agreement more strongly against the Party causing it to be drafted.
The parties acknowledge that they have agreed that the present Agreement as well as all documents and notices pursuant hereto or relating directly or indirectly hereto be drawn up in English.
(signatures follow on the next page)
- 8 -
IN WITNESS OF WHICH the Parties have duly executed this Agreement:
| ACASTI PHARMA INC. | ||
| By: |
/s/ Jan D’Alvise | |
| Name: Jan D’Alvise Title: President and CEO | ||
| /s/ LINDA P. O’KEEFE | ||
| Witness | LINDA P. O’KEEFE | |
| Executive |
- 9 -
| This ‘F-1’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| Filed on: | 9/29/17 | None on these Dates | ||
| 11/27/16 | ||||
| List all Filings | ||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 10/06/23 Acasti Pharma Inc. S-3 16:1.4M Donnelley … Solutions/FA 7/29/22 Acasti Pharma Inc. 10-K/A 3/31/22 14:1.2M Donnelley … Solutions/FA 6/21/22 Acasti Pharma Inc. 10-K 3/31/22 96:14M Donnelley … Solutions/FA 11/10/21 Acasti Pharma Inc. 424B5 1:848K Donnelley … Solutions/FA 7/15/21 Acasti Pharma Inc. 424B3 1:5.4M Donnelley … Solutions/FA 7/13/21 Acasti Pharma Inc. S-4/A 5:5.6M Donnelley … Solutions/FA 7/01/21 Acasti Pharma Inc. S-4 17:6.6M Donnelley … Solutions/FA 6/22/21 Acasti Pharma Inc. 10-K 3/31/21 92:6.3M Globenewswire Inc./FA 10/11/17 SEC UPLOAD¶ 1/19/18 1:138K Acasti Pharma Inc. |